News and research before you hear about it on CNBC et al. Claim your 1-week free trial for Street Insider Premium here.
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that Andrew J. Oakley plans to step down as chief financial officer effective March 31. 2022 and will focus on non-executive director roles. He currently sits on the boards of Union Therapeutics A / S and Novaremed AG. Andrew will remain Autolus Senior Advisor until March 2023. Dr. Lucinda Crabtree, Senior Vice President of Finance at Autolus, will be appointed CFO upon retirement.
“I would like to thank Andrew for his years of service to Autolus as Chief Financial Officer and for the impact he has had on the company and the patients we serve,” said Dr. Christian Itin, Managing Director of ‘Autolus. “With the recent agreement with Blackstone Life Sciences, it leaves Autolus in a strong financial position as we shape obe-cel’s product profile and business strategy, and we are delighted that Dr. Lucinda Crabtree, who has held several positions within the organization, will succeed him as CFO. We wish Andrew the best of luck in the next chapter of his career.
“It has been a privilege to hold the position of CFO of Autolus since 2018 and to take the company to a pivotal stage with its lead candidate, obe-cel,” said Andrew Oakley, CFO of Autolus . “I have enjoyed working with Lucinda over the past two years at Autolus, and know that I am leaving the business in good hands, supported by a strong finance team, and wish the company great success for the benefit of the people. patients and all other stakeholders.
Dr. Lucinda Crabtree joined Autolus in January 2020 and currently serves as SVP Finance. Her previous roles included Vice President of Investor Relations and Corporate Communications and most recently she led business strategy and planning, which included overseeing the financial planning and analysis function. Lucinda oversaw Autolus’ public offerings of US depository shares in 2020 and 2021 and was a key contributor to the closing of the Blackstone transaction in November 2021. Prior to joining Autolus, Lucinda’s extensive experience includes roles on the buy and sell side, particularly as a senior investment analyst and in specialist sales. In her role, she gained experience in analyzing and monitoring public and private healthcare companies and was also an observer on the board of directors of several private healthcare companies during her tenure. buyer role. Companies she has worked for include Woodford Investment Management, Panmure Gordon, Goldman Sachs, JP Morgan (who originally joined Bear Stearns) and Jefferies. Lucinda has also held positions at Grunenthal Group and AstraZeneca. Lucinda holds a Bachelor of Science in Physiology and Pharmacology from University College London and a Doctorate in Pharmacology from University College London.